(Q40381044)

English

Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors

scientific article published on 10 August 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 September 2017

Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors (English)

1 reference

Europe PubMed Central

20 September 2017

author name string

Gustavo Helguera

1

1 reference

Europe PubMed Central

20 September 2017

Gustavo Helguera

2

1 reference

Europe PubMed Central

20 September 2017

Jay S Dela Cruz

3

1 reference

Europe PubMed Central

20 September 2017

Christine Lowe

4

1 reference

Europe PubMed Central

20 September 2017

Patrick P Ng

5

1 reference

Europe PubMed Central

20 September 2017

Ryan Trinh

6

1 reference

Europe PubMed Central

20 September 2017

Sherie L Morrison

7

1 reference

Europe PubMed Central

20 September 2017

Manuel L Penichet

8

1 reference

Europe PubMed Central

20 September 2017

language of work or name

0 references

publication date

10 August 2005

1 reference

Europe PubMed Central

20 September 2017

1 reference

Europe PubMed Central

20 September 2017

24

1 reference

Europe PubMed Central

20 September 2017

3

1 reference

Europe PubMed Central

20 September 2017

304-316

1 reference

Europe PubMed Central

20 September 2017

The ErbB/HER receptor protein-tyrosine kinases and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Oncogenic kinase signalling

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

First-line Herceptin monotherapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

The IL-2 mediated amplification of cellular cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Characterization of lymphokine-activated killing by human peripheral blood mononuclear cells stimulated with interleukin 2 (IL-2) analogs specific for the intermediate affinity IL-2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Anti-tumor activity of interleukin-2-producing tumor cells and recombinant interleukin 12 against mouse glioma cells located in the central nervous system.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Strategies for designing and optimizing new generation vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Enhanced adjuvant effect of granulocyte-macrophage colony-stimulating factor plus interleukin-12 compared with either alone in vaccine-induced tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Combined IL-12 and GM-CSF gene therapy for murine hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Production and properties of chimeric antibody molecules

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

An IgG3-IL2 fusion protein activates complement, binds Fc gamma RI, generates LAK activity and shows enhanced binding to the high affinity IL-2R.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Amino acid sequence and post-translational modification of human interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Human/mouse chimeric monoclonal antibodies with human IgG1, IgG2, IgG3 and IgG4 constant domains: electron microscopic and hydrodynamic characterization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Granulocyte-macrophage colony-stimulating factor: pleiotropic cytokine with potential clinical usefulness

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2005.07.073

1 reference

Europe PubMed Central

20 September 2017

1 reference

Europe PubMed Central

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40381044&oldid=1896485087"